Advertisement

Tumor Biology

, Volume 36, Issue 10, pp 7521–7530 | Cite as

Expression of SIP1 is strongly correlated with LDHA and shows a significantly poor outcome in gastric cancer

  • Xuren Sun
  • Zhe Sun
  • Zhi Zhu
  • Chenyan Li
  • Junyan Zhang
  • Huimian Xu
  • Mingjun Sun
Research Article

Abstract

Smad interacting protein 1 (SIP1) plays an important role in the epithelial-mesenchymal transition (EMT) process by downregulating E-cadherin. Lactate dehydrogenase A (LDHA) is a crucial enzyme that plays an important role in the final step of the Warburg effect by converting pyruvate to lactate irreversibly. EMT and Warburg effect are the hallmarks of advanced gastric cancer progression. Recently, EMT has been thought to be implicated in cancer metabolism. In this study, we want to find whether there was a correlation between the expressions of SIP1 and LDHA in gastric cancer and whether expression of SIP1 alone or in combination with LDHA is associated with the progression of gastric cancer. In the present study, we examined SIP1 and LDHA expression by immunohistochemistry analysis on tissue microarray (TMA) containing tumor tissues and matched non-neoplastic mucosa (NNM). Prognostic value and correlation with other clinicopathologic factors were evaluated. In this study, we investigated the expression of SIP1 and LDHA in 261 cancer tissues and their matched NNM using tissue microarray. The immunohistochemistry analysis showed that the expression of SIP1 and LDHA was significantly higher in cancer tissues than in NNM (P = 0.002 P = 0.000, respectively). The expression of SIP1was significantly associated with age, Lauren grade, and histologic differentiation (P < 0.05). The expression of SIP1 was strongly correlated with LDHA expression in gastric cancer (P = 0.000, R = 0.589). The combined expression of SIP1 and LDHA was significantly associated with age, Lauren grade, and histologic differentiation (P < 0.05). Survival analysis demonstrated that the expression of SIP1 or LDHA was associated with significantly shorter overall survival (OS) (P = 0.003, P = 0.000, respectively) and disease-free survival (DFS) (P = 0.003, P = 0.000, respectively). The combined expression of SIP1 and LDHA was associated with less survival time in gastric cancer patients (P = 0.000). The multivariate analysis showed that the expressions of SIP1 and LDHA in gastric cancer (GC) were independent prognostic factors for OS (hazard ratio = 1.465, 95 %CI 1.128–1.901, P = 0.004, hazard ratio = 1.514, 95 %CI 1.091–2.101 P = 0.013, respectively) and DFS (hazard ratio = 1.461, 95 %CI 1.130–1.890, P = 0.004, hazard ratio = 1.550 95 %CL1.119–2.147 P = 0.008, respectively). Our study indicated that expressions of SIP1 and LDHA are independent prognostic factors in gastric cancer patients and may be predictive of poor outcomes.

Keywords

SIP1 LDHA Gastric carcinoma Tissue microarray Prognosis 

Notes

Acknowledgments

This study was supported by grants from Research Fund for the Doctoral Program in College of Chinese Education Department (No.20102104110004) and scientific and technological projects of Liaoning Province Science and Technology Department (Nos. 2009225011-2 and 2013225049).

Conflicts of interest

None

References

  1. 1.
    Goggins WB, Wong GK. Poor survival for US Pacific Islander cancer patients: evidence from the surveillance, epidemiology, and end results database: 1991 to 2004. J Clin Oncol. 2007;25:5738–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Wittekind C, Neid M. Cancer invasion and metastasis. Oncology. 2005;69 Suppl 1:14–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 2007;24:587–97.CrossRefPubMedGoogle Scholar
  9. 9.
    Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2:84–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76–83.CrossRefPubMedGoogle Scholar
  11. 11.
    Vernon AE, LaBonne C. Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol. 2004;14:R719–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Perez-Moreno MA, Locascio A, Rodrigo I, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem. 2001;276:27424–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002;62:1613–8.PubMedGoogle Scholar
  14. 14.
    Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7:1267–78.CrossRefPubMedGoogle Scholar
  15. 15.
    Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun. 2009;384:6–11.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer. 2000;36:1607–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002;161:1881–91.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ohta H, Aoyagi K, Fukaya M, et al. Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer. 2009;100:389–98.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang SH, Zhu RX, Li L, Li CT. Forensic application of investigator Argus X-12 kit in Han population from East China. Fa Yi Xue Za Zhi. 2011;27:365–8.PubMedGoogle Scholar
  21. 21.
    Elloul S, Elstrand MB, Nesland JM, et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103:1631–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Yoshihara K, Tajima A, Komata D, et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 2009;100:1421–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Imamichi Y, Konig A, Gress T, Menke A. Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene. 2007;26:2381–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Maeda G, Chiba T, Okazaki M, et al. Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression. Int J Oncol. 2005;27:1535–41.PubMedGoogle Scholar
  25. 25.
    Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.PubMedGoogle Scholar
  26. 26.
    Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. Curr Opin Rheumatol. 2007;19:44–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lewis BC, Shim H, Li Q, et al. Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol. 1997;17:4967–78.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94:6658–63.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yao F, Zhao T, Zhong C, Zhu J, Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 2013;34:25–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Sun X, Sun Z, Zhu Z, et al. Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients. PLoS ONE. 2014;9:e91068.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Vergara D, Simeone P, Latorre D, et al. Proteomics analysis of E-cadherin knockdown in epithelial breast cancer cells. J Biotechnol 2014.Google Scholar
  33. 33.
    Sun Y, Daemen A, Hatzivassiliou G, et al. Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab. 2014;2:20.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Place TL, Nauseef JT, Peterson MK, Henry MD, Mezhir JJ, Domann FE. Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition. PLoS ONE. 2013;8:e83021.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jiang L, Xiao L, Sugiura H, et al. Metabolic reprogramming during TGFbeta1-induced epithelial-to-mesenchymal transition. Oncogene 2014;0.Google Scholar
  36. 36.
    Chu K, Boley KM, Moraes R, Barsky SH, Robertson FM. The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget. 2013;4:446–62.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Rong Y, Wu W, Ni X, et al. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 2013;34:1523–30.CrossRefPubMedGoogle Scholar
  38. 38.
    Dai YH, Tang YP, Zhu HY, et al. ZEB2 promotes the metastasis of gastric cancer and modulates epithelial mesenchymal transition of gastric cancer cells. Dig Dis Sci. 2012;57:1253–60.CrossRefPubMedGoogle Scholar
  39. 39.
    Hamabe A, Konno M, Tanuma N, et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2014;111:15526–31.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xuren Sun
    • 1
  • Zhe Sun
    • 2
  • Zhi Zhu
    • 2
  • Chenyan Li
    • 3
  • Junyan Zhang
    • 2
  • Huimian Xu
    • 2
  • Mingjun Sun
    • 1
    • 4
  1. 1.Department of GastroenterologyFirst Affiliated Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Surgical OncologyFirst Affiliated Hospital of China Medical UniversityShenyangChina
  3. 3.Department of Endocrinology and MetabolismFirst Affiliated Hospital of China Medical UniversityShenyangChina
  4. 4.Department of Gastrointestinal EndoscopyFirst Affiliated Hospital of China Medical UniversityShenyangChina

Personalised recommendations